NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)

The summary for the NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional): This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013. The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nations research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.

Federal Grant Title:	NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-RM-20-020
Type of Funding:	Grant
CFDA Numbers:	93.310
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 30th, 2020
Original Application Deadline:	September 30th, 2020
Posted Date:	May 21st, 2020
Creation Date:	May 21st, 2020
Archive Date:	November 5th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	May 21st, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...; • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...; • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional); • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional); • Using Metabolomics to Investigate Biological Pathways and Networks (R01); • Assay Development for High Throughput Molecular Screening (R21); • Membrane Protein Production and Structure Determination (R01)
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...